DJ Steve Aoki donates $20K and teams up with WVU Rockefeller Neuroscience Institute – WBOY.com

MORGANTOWN, W.Va. World-renowned DJ and two-time Grammy-nominated producer Steve Aokiis taking his collaborations to a whole new level by partnering with the WVU Rockefeller Neuroscience Institute (RNI), to which he donated $20,000.

The collaboration came about after Aoki and RNIs Executive Chair Dr. Ali Rezai both spoke at the Collision conference, a major tech event that drew more than 32,000 virtual attendees in 2020. According to a release, the two immediately connected over their shared interest in neuroscience. After learning about the innovative work RNI does with conditions like addiction, Alzheimers, and dementia, Aoki decided to donate $20,000.

Were were pleased, Rezai said. I wasnt surprised because I know Steve and Steve Aoki Foundation have a great interest in raising awareness for people who have a neurological condition, brain science, and technology.

The donation announcement came during a virtual Celebrity Pokemon Box Break with Aoki and #RealKingPokeon, a Pokemon-focused streaming event hosted on the gaming platform Twitch. Rezai said roughly 6,000 people were watching when the check was presented.

That is significant, RNIs executive chair said, because Aoki uses his celebrity to bring awareness to issues many are not aware of. Case in point, there are about five million people in the U.S. with Alzheimers and roughly 100 million suffering from neurological problems, so awareness needs to be raised.

By using his platform, Rezai said, Aoki is really making a difference.

That really helps us raise awareness. The donation that was provided helps us have community programs here for support groups for people with addiction, support groups for people with Alzheimers disease and helps us raise awareness and provide our community services for the region that we do for patients and their families who are impacted by dementia, Alzheimers and addiction. So very helpful and this is what we need, its more awareness.

This is why Rezai said RNI is very appreciative of Aoki and his foundation. They are passionate about mental health and proved it, he said.

Rezai hopes to see more celebrities doing the same thing in the future. He doesnt think all the attention has to go to RNI and neuroscience, but awareness needs to be brought to critical health issues. He went as far as saying its fundamental for celebrities to use their influence for good because it helps support patients and their families.

When other celebrities follow in Aokis footsteps, they will create connections with new communities. That is what Aoki has done, Rezai said.

Through his connection with RNI, he now has forged a relationship with West Virginia. Rezai said Aoki is even using a smart ring RNI designed to monitor health metrics. Plus he added the DJ expressed a great deal of interest in visiting West Virginia.

Hes using our technology and his creativity and his art and science is helping accelerate the understanding of neuroscience and brain conditions, Rezai said. Its all linked together, so were really appreciative for our partnership with Steve and the steve Aoki Foundation. We look forward to having him visit West Virginia and come here and speak to the people who love him here and also raise further awareness.

Continued here:
DJ Steve Aoki donates $20K and teams up with WVU Rockefeller Neuroscience Institute - WBOY.com

The sculptural white mesh of Perkins & Will’s Gardner Neuroscience Institute stands out in a sea of brick – The Architect’s Newspaper

In an age where healthcare design is rapidly embracing new technologies and research to maximize patient care and comfort, the University of Cincinnatis Gardner Neuroscience Institute stands out with its attention to detail for the specialized needs of the patients and healthcare workers who use the space. The outpatient facility, chosen as ANs 2019 Best of Healthcare Design winner, was designed to consolidate 15 specialty centers for treating patients suffering from neurological diseases while accommodating 125 faculty members in one gateway space for the medical campus. Perkins&Will, based in Chicago only a short drive away, was able to translate these needs into a design that considered the patient from the inside out.

The building is distinct among its brick neighbors due to its almost sculptural facade; waves of white mesh encapsulate the sun-facing sides of the building with a glass curtain wall facing inward toward the UC Health campus. The institute creates a new visual identity, separate from the imprint that Frank Gehrys voluminous brick Vontz Center for Molecular Studies, frequently in need of repair, leaves next door.

The four-story steel-and-glass structure rose on the sloped corner of the medical campus, along a major six-lane street, ringing in at nearly 200,000 square feet. The research team at Perkins & Wills Human Experience Lab spoke with many patients, family members, and faculty to help the design team create more than an architectural statement, but also an envelope that interacted with the interior as informed by patient experience. It opened up the conversation to much broader, deeper aspects. We heard about everything from how dramatically difficult it is for someone with a neurological disorder to find a parking spot to getting into the building in a timely manner and their need to access a toilet quickly, all of which can make the journey to the hospital a horrific experience, said Eve Edelstein, director of the Human Experience Lab.

The architects worked with Structurflex to land on a structural facade with tensile fabric mesh that emphasized panoramic views and daylight while still diffusing sun for neurological patients who might be sensitive to light. The resultant mesh facade, manufactured by Mehler Texnologies out of Germany, is made of over 30,000 square feet of coated PES (polyvinyl-coated polyester). It diffuses sunlight directing it at an angle through the glass curtain wall, minimizing glare while reducing the solar load by over 56 percent. Additionally, incorporating the outer screen into the facade design eliminated the need for costly internal shades.

Although derived from a desire to protect sensitive patients and improve energy performance, the mesh facade has become a symbol for UC health. The advanced facade speaks to the technical excellence of UC Healths program while the soft organic geometries reflect the humane personal care UC Health gives to its patients, said Jerry John, design principal at Perkins & Will.

The sea of panels cover the top three stories and wrap around the cantilever on the south side of the building and are held by a continuous aluminum clip system developed by Facid North America. The tensioned clips system is attached to a unitized steel subframe that is supported by the buildings steel superstructure. The steel subframe is primarily hung from the top of the roof and laterally restrained at the bottom. A standard panel module is 10-feet-wide-by-47-feet-tall. This scale not only effectively places the building in its urban context, but also is showcased at the human scale when those circulating through the glass hallways can connect to the details of the textured facade on any level.

See the article here:
The sculptural white mesh of Perkins & Will's Gardner Neuroscience Institute stands out in a sea of brick - The Architect's Newspaper

My Doctor Told Me My Pain Was All in My Head. It Ended Up Saving Me. – Slate

It began with a pulled muscle. Each day after school, as the sun sank dusky purple over the hills of my hometown, Id run with my track teammates. Even on our easy days, Id bound ahead, leaving them behind. It wasnt that I thought myself better than themits that when I ran fast, and focused on nothing but the cold air burning my lungs and my feet pounding, my normally anxious thoughts turned to white noise. Until, one day, something popped in my leg. I stopped. I limped a little, and then tried running again: sharp, hot pain radiated down my thigh. Panic flooded me, as I imagined weeks without running: weeks without a predictable break from my own thoughts, weeks immersed in adolescent loneliness. I was 14. Pain was about to define a decade of my life.

First, I took a break from the sportfive months of stretching, icing, and waiting for the leg to heal. I returned to running, but soon after, I developed a throbbing pain in my back. The cycle repeated. Less than a year later, the pain showed up again, this time in my foot. My focus on healing my body became singular: I tried physical therapy and massage and acupuncture. I researched conditions that could lead to repeat injury. Maybe I had a rare soft-tissue disorder, I thought, or maybe early-onset rheumatoid arthritis. I let an osteopath stick a giant needle into my spinal ligaments, and inject me with sugar water, which is just as painful as it sounds. After a chiropractor recommended an anti-inflammatory diet, I subsisted on only meat and vegetables.

In many cases, pain outlasts injury and refuses to abate with treatments focused on healing thebody.

Id get a few good monthsa joyful summer, a successful cross-country season. Then the pain would return again. As I prepared to leave home for college, my knees and ankles throbbed. For several months, my hip hurt so badly I dreaded even walking to the dining hall. Then, while scrambling to finish my senior thesis, neck spasms prevented me from leaving my bed for days. When I saw doctors, I hoped that they would discover something terribly wrong. They never did. Have you tried psychotherapy? one asked me. I had. Id been in therapy for years.

When I eventually limped into the waiting room of a chronic pain specialist at New York University, it was my last-ditch effort before leaving the city and putting my graduate studies in science journalism on hold. I was incapacitated by a sharp popping sensation in my arms and burning in my hands and feet. I couldnt climb a flight of stairs, type on a computer, or grasp the handrail of a subway car without pain. I would arrive at class or work already exhausted from the effort of getting there.

The clinician listened to the story of my search for relief. He gave me a thorough examination. Then, he sat down across from me, looked me in the eye, and smiled as he told me that I was in excellent health. My pain was happening in my head. This answer was familiar. But unlike other physicians, this doctor didnt seem perplexed by my pain. He assured me he believed that my pain was real, and that he was confident Id get better. He had something to give me that would help.

In medical school, little time is devoted to painjust 11 hours of lectures on average, according to an evaluation of more than 100 medical schools published in the Journal of Pain. Instruction on pain focuses almost entirely on elucidating a physical cause and fixing it, said James Hudson, medical director of the pain rehabilitation program at Mary Free Bed Rehabilitation Hospital in Grand Rapids, Michigan. Checking for signs of physical damage is an appropriate and necessary response to pain. A sudden searing pain in your knee might signal a torn ligament and require surgery and rest. But pain experts say that this understanding of pain, as a sign of physical damage, is woefully incomplete. Pain exists to warn us of danger, Hudson said. But when pain becomes chronic, as it does for around 20 percent of Americans, it often stops serving that purpose. Chronic pain lasts longer than three to six months. It may have a physical causeit could be a sign of cancer or a gastrointestinal illness, for exampleand all my doctors appointments to rule one out were important. But in many cases, pain outlasts injury and refuses to abate with treatments focused on healing the body.

Contrary to how most people think of it, pain is more than just a message sent from point A (our body) to point B (our brain), said Luana Colloca, a pain neuroscientist at the University of Maryland School of Nursing. Instead, its more accurate to characterize pain as our brains interpretation of that messagean interpretation influenced by our emotions, thoughts, and beliefs. Pain might be a warning worth heeding; it might be a wild distortion of reality. This is the central message of pain neuroscience education, or PNE, which is what the clinician at NYU prescribed for me. PNE does not involve drugs or physical exercise. It was an unlearning of everything I knew about pain, in exchange for a new truth: My chronic pain wasnt an indicator of physical damage in my body.

PNE was developed in the early 2000s, when Australian pain scientist Lorimer Moseley began delivering hourslong lectures on pain neuroscience to patients with lower back pain. At that time, it was common practice for these patients to attend back school, where theyd learn about spine anatomy, proper ergonomics, and how to safely lift thingsthe kinds of things that help protect the back from further physical damage, but dont necessarily change the pain someone already experiences. Moseleys research found that back school didnt seem to help these patientsbut teaching them about the brain did. In the research world, Moseleys ideas caught on quickly. Just a few years after his first clinical trial of PNE, the intervention began appearing in leading scientific journals, including the prestigious journal Pain. In the clinical world, its taken much longer to gain ground, said Daniel Clauw, director of the Chronic Pain and Fatigue Research Center at the University of Michigan Medical School. Recently, hes been noticing more general physicians and physical therapists talk about the need for PNE. Its crept into the clinical fields, Clauw said. Its not a tsunami. Its more of a slow ooze.

At its heart, PNE is pretty simple. One of the most common metaphors used in lectures describes pain as a smoke detector: Its there to warn us of danger, but isnt always totally reliable. Sometimes theres a fire; sometimes its just your toast burning again. And sometimes the detector fails to go offthere can be damage to the body without any pain at all. In 1989, researchers at George Washington University Medical Center performed MRIs on 67 volunteers, none of whom had ever experienced back pain or sciatica. The study, published in the Journal of Bone and Joint Surgery, found that about one-third of them had a substantial abnormality, including spinal stenosis and herniated disksconditions often attributed to chronic back pain. Remember, none of these volunteers had any symptoms. Seven years later, a follow-up study found that about half of the volunteers did go on to have back painbut a solid half of that group had no physical defects. A more recent review, in the British Journal of Sports Medicine, combined the results of many different studies and found that between 19 and 43 percent of people 40 years of age and older with no knee pain actually had physical signs of arthritis.

Then theres the electric guitar metaphor, to which Clauw is partial. He explains to patients that the brain can act like an amplifier on an electric guitar: As it receives signals, it can turn the dials up and down, producing wildly different sounds from the same input. Fear, for example, turns the dial up. So when people react with panic to their pain, fearing that their pain will only continue to get worse, it acts like a self-fulfilling prophecy. In one study, published in 2017 in the European Journal of Pain, scientists followed 104 young men for three months after receiving back surgery. The strongest predictor of persistent paina common complication of the surgerywas the participants anxiety about their pain and tendency to pay attention it. Another way the dial can turn up: Chronic-pain sufferers learn to expect pain with specific movements or activities, bracing for it before it even starts. This expectation can create a phenomenon called the nocebo effectwhat neuroscientists like to call the evil twin of the placebo effect. When you expect pain, it primes your nervous system to amplify the most innocuous sensations and interpret them as pain. To extend the guitar amplifier metaphor: The brush of a string might sound like a resonating boom.

A central goal of PNE is to teach patients that they can control that amplifier or smoke detectorhowever you might think of your brains system for interpreting what your body is telling it. Nowadays, PNE comes in many forms. It might be a brief explanation given by clinicians in tandem with physical therapy or cognitive behavioral therapy. It might be an intensive lecture series and take-home worksheets. I was offered a lecture series and a support group. My graduate student insurance didnt cover these services, so I went the DIY route: Alongside regular follow-ups with my chronic pain specialist, I turned to a multitude of workbooks, YouTube videos, and phone applications, all of which teach users about pain. I listened to interviews with chronic-pain researchers and to testimonials from former chronic-pain patients, explaining how changing their mind about pain helped them recover. I personally came to think of my pain as a neurotic parent who was doing their best to protect me, but whose hand-wringing I need to take with a grain of salt.

What PNE is consistently good at is helping patients feel less anxious about their pain. Recently, pain scientists combined the results of 16 different studies on PNE, ranging in size from 12 to 120 participants. Their results, published in 2019 in the Journal of Pain, found that patients who received PNE were less afraid of activity and spent less time ruminating over their condition. In one of the studies covered in that review, scores measuring patients fear of movement decreased from an average of 28.7 on a 44-point scale to 16.1 for those who received PNE along with physical therapy. In a control group that only received physical therapy, scores decreased to only 24.1. That decrease in fear can translate into an increase in the ability to move, complete tasks, and participate in daily activities. In another study, which combined PNE and aquatic therapy, 72.4 percent of participants who received PNE experienced long-term improvements, compared with 44.4 percent of those who only received the therapy. Its important to note that PNE is likely not working alone in these cases. Pain scientists emphasize that while PNE can have its own therapeutic benefit, it often acts as a foundation for other treatments, such as physical therapy that gradually introduces feared or painful movements.

My feet smarted, but I grinned as they pounded thepavement.

Since I was working my way through treatment mostly on my own, in addition to watching videos about nerve synapses, I learned to make lists of all my anxieties and to meditate to calm the fear of my own pain as I tried to go about my life. I remember a long walk I took on a Saturday morning shortly after I began PNE. The pain still radiated through my feet and ankles, but knowing that it wasnt going to hurt me, I let it fade into the background. Instead of focusing on it, I remember noticing the way the early autumn light fell on the brownstone-lined streets, and thinking about breakfast. Within weeks, I began to notice that the pain wasnt so bad.

No longer worrying that it would worsen with exercise, I dug my running shoes out from under my bed. At first, I just ran for one block. My feet smarted, but I grinned as they pounded the pavement. The rhythm was familiarit took me back to the joy of running alone at sunset as a teenager. The next day: two blocks.

Most people only experience small, temporary improvements in pain after PNE, if they experience any change at all. An analysis of five clinical trials found that participants pain didnt decrease on averagebut up to 45 percent of them experienced more than a 10 percent change in their pain. However, there are case studies that document patients who experience near total recovery after PNE. Pain researchers dont totally understand why responses to PNE vary, why the smoke alarms in some brains seem to be simply broken, even in the face of repair efforts. I asked Akiko Okifuji, a pain researcher at the University of Utah Health, why some patients recover totally and others dont. She laughed. Thats the golden question.

What can make pain worse, however, is the cycle of being told that everything is just fine, without the help of a program or expert guiding you through whats happening in your head. When I first began experiencing pain, my running coach tried to tell me that because my pain moved around my body, it probably didnt have a physical cause. I took extreme offense at his dismissiveness. When doctors could not find a physical cause and summarily sent me on my way, the result was a spiral of frustration and worsening pain. I began to wonder if I was just dramatic or a hypochondriac. In a study published in the journal Pain, researchers found that clinicians are more likely to judge the chronic pain female patients report as exaggerated, less likely to offer pain medication, and more likely to offer psychiatric referralsbut without the specific recommendation of PNE. Regardless of the pains cause, they dont anticipate that it might affect patients lives nonetheless, said Amanda Williams, a professor of clinical health psychology at University College London and an author on that study. Health care professionals walk a fine line when communicating with patients about their pain, she explains. Dismissal can trigger fear. Fear can worsen pain.

In contrast, I found PNE deeply validating: It assured me that there was something wrong, something that I could work on. These psychological components dont mean the pain isnt real, Okifuji told me. Its a real phenomenon. Its a biological phenomenon. Most importantly, PNE offered me hope. Youre young, youre healthy. Im confident youll get better, my pain doctor told me.

It might have been an exaggeration of the odds, but he turned out to be right. In January, I drove out to a nature park in the middle of a weekday. The fields were golden-brown, and rain fell in a spray. The rhythm of my breath and feet drowned out my thoughts. As I hammered a hill, I felt a familiar twinge in my foot. I stopped and walked and felt my hot skin interfacing with the cold air. As I started running again, the pain became as innocuous as the burning in my lungs. And then, it was gone.

Continued here:
My Doctor Told Me My Pain Was All in My Head. It Ended Up Saving Me. - Slate

Global Neuroscience Market Analysis on Historical Development and Future Forecast to 2025 KSU | The Sentinel Newspaper – KSU | The Sentinel Newspaper

MarketQuest.biz proclaims the addition of a new research report titled as, Global Neuroscience Market 2020 by Company, Regions, Type and Application, Forecast to 2025 that contains the industrial chain, factual data about every single part of the Neuroscience market, production chain, manufacturing capacity, sales volume, and revenue. The report starts with a brief introduction and market overview of the industry with estimates of market scope and size. According to the report, the global Neuroscience market has been developing at a higher pace with the development of imaginative frameworks and a developing end-client tendency. The report showcases an overview of the market scope, players, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Analysis of Market Effect Factors:

The report contemplates the global industry market size, industry status and gauge, rivalry scene, and development opportunity. The drivers, limitations, and opportunities for the market are also listed along with current trends in the industry. The market report is categorized by application, end-user, product/service types, and other, as well as by region. Players around various regions are covered under this report. The report contains analysis and market concentration of the key players in the market, along with their market presence analysis by region and product portfolio. As per the report, the Neuroscience market report points out national and global business prospects and competitive conditions.

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/12410

Competitive analysis:

Competitive and company share analysis has been given in the report. The study highlights the presence of several major and leading vendors in the Neuroscience market. The key players are included in the report with broad analysis with coverage of price, revenue, cost, company profile, contact credentials, and among others. The report also gives future demand, the quantity of production, required raw material, and the health of the organization.

With an emphasis on strategies, there have been several primary developments done by major companies such as: GE Healthcare, Plexon, Mightex Bioscience, Siemens Healthineers, Tucker-Davis Technologies, Noldus Information Technology, NeuroNexus, Blackrock Microsystems, Thomas RECORDING GmbH, Phoenix Technology Group, Alpha Omega

On the basis of types, the market is primarily split into: Whole Brain Imaging, Neuro-Microscopy, Electrophysiology Technologies, Neuro-Cellular Manipulation, Stereotaxic Surgeries, Animal Behavior, Other

On the basis of applications, the market covers: Hospitals, Diagnostic Laboratories, Research Institutes, Other

Regional Segmentation And Analysis To Understand Growth Patterns: The market has been segmented into major regions to understand the global development and demand patterns of this market. By region, the global Neuroscience market has been segmented in North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

ACCESS FULL REPORT: https://www.marketquest.biz/report/12410/global-neuroscience-market-2020-by-company-regions-type-and-application-forecast-to-2025

Credible Targets of The Industry Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketquest.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketquest.bizWeb: http://www.marketquest.biz

Excerpt from:
Global Neuroscience Market Analysis on Historical Development and Future Forecast to 2025 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper

Neurons from patient blood cells enable researchers to test treatments for genetic brain disease – Brown University

PROVIDENCE, R.I.[Brown University] New research provides insights into the treatment of Christianson syndrome (CS), an X-linked genetic disease characterized by reduced brain growth after birth, intellectual disability, epilepsy and difficulties with balance and speech.

One of the major challenges in developing treatments for human brain disorders, like CS, is developing an experimental system for testing potential therapeutics on human neurons, said study senior author Dr. Eric Morrow, an associate professor of molecular biology, neuroscience and psychiatry at Brown University. In recent years, advanced stem cell therapies that use tissues from patients have provided powerful new approaches for engineering human neurons from the patients themselves, who may undergo the treatment in the future.

For the study, published in Science Translational Medicine on Feb. 10, 2021, Morrow and his colleagues obtained blood samples from five CS patients and the patients unaffected brothers. They then reprogrammed these blood cells into stem cells, and these stem cells were converted into neurons in a petri dish. As a result, they obtained neurons that were representative of those from CS patients, and they used these neurons to test treatments.

Morrow who directs the Center for Translational Neuroscience at the Carney Institute for Brain Science and the Brown Institute for Translational Science said the team also used a new gene-editing approach that employs CRISPR-Cas9 technologies to correct patient mutations back to a healthy gene sequence.

CS is caused by a mutation in a gene encoding for NHE6, a protein that helps regulate acid levels within cell structures called endosomes. Past research suggests that the loss of NHE6 causes endosomes to become overly acidic, which disrupts the abilities of developing neurons to branch out and form connections in the growing brain.

Loss of this important protein can arise from a variety of gene mutations in patients. The majority of CS mutations are called nonsense mutations, which prevent NHE6 from being produced at all; four of the five CS patients involved in this study exhibited this class of mutation. However, some CS patients exhibit missense mutations. Individuals with missense mutations still have some NHE6, but it is produced in smaller amounts, and the protein fails to function as it should.

The research team tested two main forms of treatment on the stem-cell-derived neurons: first, gene transfer, which involves adding a healthy NHE6 gene into the cell; and second, administration of trophic factors, which are substances that promote neuron growth and encourage neurons to develop connections with other neurons. The researchers found that the neurons response to treatment depended on the class of mutation present.

The gene transfer studies, which may represent the first steps toward developing gene therapy, were successful in neurons with nonsense mutations. After the researchers inserted a functional NHE6 gene into nonsense-mutation CS neurons, the neurons branched out properly. In neurons with missense mutations, however, gene transfer failed completely. Further tests suggested that the abnormal NHE6 produced as a result of missense mutations may interfere with normal NHE6, thereby rendering gene transfer therapy ineffective in patient cells with these mutations.

In contrast, administration of trophic factors, such as brain-derived neurotrophic factor (BDNF) and insulin-like growth factor-1 (IGF-1), successfully promoted proper branching in all the CS neurons studied, regardless of mutation type.

While these initial results are encouraging, Morrow hopes that future studies will examine these treatments in animal models.

Our results provide an initial proof-of-concept for these treatment strategies, indicating that they should be studied further, he said. However, we may ultimately need to pay close attention to the class of mutation that a patient has when we choose a specific treatment.

In addition to Morrow, the research team included scientists from Brown University, the University of South Carolina and the Icahn School of Medicine at Mount Sinai. The study was supported by multiple grants from the National Institutes of Health as well as a number of awards from foundations and academic institutions.

This news story was authored by contributing science writerKerry Benson.

Read more:
Neurons from patient blood cells enable researchers to test treatments for genetic brain disease - Brown University

What the Flow Halo acquisition means for mental health medtech – Medical Device Network

On 5 February, Flow Neuroscience announced that it had acquired the technology, R&D and patents of fellow brain stimulation tech developer Halo Neuroscience for an undisclosed sum.

While both companies use transcranial direct current stimulation (tDCS) in their products, they have had slightly different focuses up until this point. Flow, headquarted in Malm, Sweden, has created a medically-approved brain stimulation device designed to treat depression, while US-based Halo has been developing neuromodulation technology to improve movement, cognitive performance and wellbeing.

tDCS involves sending a constant, very weak current into the brain via electrodes on the head.

Flow aims to use Halos research to enhance its tDCS depression headset and expand treatment to include mental health issues that are commonly comorbid with depression, as well as collaborating with clinicians to address other pressing medical needs such as rehabilitation and motor impairment.

Halo co-founder and CEO Brett Wingeier will now be supporting Flow as an advisor.

People with depression have been found to have lower neural activity in the left frontal lobe, the area of the brain associated with cognitive skills and emotional expression.

Flows tDCS headset aims to remedy this by delivering a constant, low direct current via electrodes to stimulate neurons in this area. The headset is used in conjunction with Flows depression app, which guides users through a series of personalised exercises informed by behavioural therapy techniques.

Halos headset stimulates a different part of the brain the motor cortex, an area involved with planning, control and the execution of voluntary movements. Its built into a pair of over-ear headphones, which users are encouraged to wear during exercise.

The company has been working with leading researchers including theat the City College of New Yorkand theAir Force Research Laboratoryin Ohio to further develop its neuromodulation technology.

GlobalData's TMT Themes 2021 Report tells you everything you need to know about disruptive tech themes and which companies are best placed to help you digitally transform your business.

Like many consumer-focused companies, Halo appears to have struggled during the Covid-19 pandemic. Its website currently states that due to current circumstances its product line has been discontinued.

Flow co-founder and chief technology officer Erik Rehn said: We are building on the technology Halo applied for the improvement of performance and well-being, which will revolutionise the application of tDCS for mental health disorders. By combining different neuromodulation techniques, we will be able to personalise treatments further to target brain regions with more precision. This will allow us to innovate treatments which are patient-specific and even more efficient and reliable.

As well as incorporating Halos work into its own research, Flow has the opportunity to branch out from depression treatment and enter the consumer and wellness market. It could opt to begin marketing the Halo Sport product line as-is, or release an upgraded product which is still ultimately intended for use during exercise.

However, theres no indication of this just yet, and the company may instead choose to stay in the medical area.

The Covid-19 pandemic has been dubbed the greatest threat to mental health since the Second World War, with an additional ten million people thought to need new or additional mental health support as a result of the crisis. To compound this, the NHS and other health systems around the world have found themselves at full capacity, leaving many people unable to access traditional mental health care.

Theres also the impact of so-called long Covid to consider post-viral symptoms that continue after an acute Covid-19 infection has passed. These can include fatigue, headache, breathlessness, continuous cough, hearing and eyesight problems, headaches and loss of smell and taste. Flow has said it wants to focus on tDCS for rehabilitation, and long Covid recovery could fit neatly into this.

In a statement, Flow co-founder and CEO Daniel Mansson described Halos technology and academic research as complementing Flows in an almost magical way. With more and more neurostimulation devices hitting the market, Flow is definitely one to watch over the coming months.

Cleaning Fluids, Surface Coatings and Dry Lubricants for Medical Device Manufacturers

28 Aug 2020

Simulation Equipment and Virtual Reality-Enabled Lessons for Medical Students

28 Aug 2020

See the article here:
What the Flow Halo acquisition means for mental health medtech - Medical Device Network

New study uncovers link between perception of time and sense of touch – News-Medical.Net

The percept of time relates to the sense of touch.

A new SISSA study "A sensory integration account for time perception" published in PLOS Computational Biology uncovers this connection.

"The challenge to neuroscience posed by the sense of time lies, first and foremost, in the fact, there do not exist dedicated receptors - the passage of time is a sensory experience constructed without sensors," notes Mathew Diamond, director of the Tactile Perception and Learning Lab.

"One might imagine a precise clock in the brain, a sort of stopwatch that registers the start and stops and computes the elapsed time between those two instants. But decades of research have not found any brain mechanism resembling a stopwatch. We thought that understanding sensory systems might be the key to understanding a sense of time."

The lead author of the study, SISSA Ph.D. student Alessandro Toso, explains how the team (including also Arash Fassihi, Luciano Paz and Francesca Pulecchi as co-authors) approached the problem:

"We trained both humans and rats to compare the durations of two tactile vibrations. The main clue leading to the new theory is that the perceived duration of vibration increases not only in relation to actual elapsed time but also in relation to the intensity of the vibration. In other words, subjects (of both species) feel that a stronger vibration lasts longer."

The team then proposed a model where the experience of the elapsed time accompanying a stimulus is generated when the neuronal representation of the stimulus itself is collected and summated by a downstream accumulator.

This model would explain both characteristics of sense of time: a stimulus is judged as long when it is, in fact, longer, but also when its higher intensity evokes a larger sensory response. They tested the plausibility of the model by simulating the time percept that would emerge through the integration of the neuronal firing of real spike trains recorded from the sensory cortex of rats receiving the vibratory stimulus.

The close match of the model's prediction of perceived time to actual perceived time for the same stimuli supports the model. Now the research will continue with the identification and analysis of the accumulator.

For many years, this research group has been interested in touch perception and memory. Following unexpected findings, our curiosity has led to a new research line, time perception. This brings us in synergy with Domenica Bueti, SISSA neuroscientist with an outstanding track record in time perception. We are looking forward to collaborating."

Mathew Diamond, Director of Tactile Perception and Learning Laboratory

Source:

Journal reference:

Toso, A., et al. (2021) A sensory integration account for time perception. PLOS Computational Biology. doi.org/10.1371/journal.pcbi.1008668.

More here:
New study uncovers link between perception of time and sense of touch - News-Medical.Net

The COVID Vaccine: A Shot in the Arm for Fertility Treatment? – BioNews

8 February 2021

The rollout of COVID vaccination programmes has brought with it a renewed hope of a return to normality but has also raised questions about the impact of vaccinationon fertility treatment and pregnancy.

To help explain and clarify the advice to fertility patients and clinicians, and to fight misinformation spreading online, the Progress Educational Trust (PET) the charity that publishes BioNew held an online event.

'The COVID-19 Vaccine: A Shot in the Arm for Fertility Treatment?' was chaired by PET's director Sarah Norcross, and featured speakers outlining the approaches taken by UK, EU and US bodies.

Professor Jason Kasraie, chair of the Association of Reproductive and Clinical Scientists (ARCS), gave the first presentation an overview of the UK guidance issued by ARCS and the British Fertility Society (BFS). He emphasised that there is no known risk in giving non-live vaccines to pregnant women or those looking to conceive.

ARCS and BFS say there is no need to avoid pregnancy after vaccination, and women who would benefit from the vaccine should receive it without compromising their planned fertility treatment. However, as with any medical treatment, patients should be involved in the decisionmaking process. Pointing out the prevalence of fearmongering misinformation online, Professor Kasraie stressed the importance of being careful about how risk is communicated, when there is currently no cause for fear.

The next speaker, Dr Anna Veiga, coordinator of the European Society of Human Reproduction and Embryology (ESHRE)'s COVID-19 Working Group, explained that ESHRE's relatively cautious position relates to an absence of concrete evidence.

ESHRE has decided not to offer a universal recommendation on whether or not men and women attempting assisted conception should get vaccinated before starting treatment, and instead emphasises the importance of weighing up the factors that are relevant to each individual patient. ESHRE recommends postponing the start of fertility treatment for at least a few days after the vaccine, to allow the immune response to settle.

Regarding vaccination and pregnancy, ESHRE suggests that pregnant women should not be vaccinated unless they are at particularly high risk. ESHRE also suggeststhat if a woman becomes pregnant after receiving the first vaccine dose then, then unless the woman is at particularly high risk the second dose should be delayed until the pregnancy is over. There is no advice to avoid pregnancy after vaccination.

Despite this cautious approach towards the vaccine, Dr Veiga noted that pregnant women have been shown to be at higher risk of developing severe COVID-19 compared to non-pregnant women. Women may therefore still decide to go ahead with vaccination, since the benefits of protection from COVID-19 might outweigh any theoretical risks from, vaccination.

Dr Sigal Klipstein, member of the American Society of Reproductive Medicine (ASRM)'s COVID-19 Task Force, explained that the ASRM's more permissive advice is based on assessing the known and very real risks of COVID-19 alongside the largely theoretical risks of the vaccine. As such, the ASRM recommends vaccination to everyone who can access the vaccine whether before or during pregnancy on the grounds that the benefits outweigh the risks.

To emphasise this point, Dr Klipstein gave the example of Israel's decision to make pregnant women a priority group for vaccination, due to their increased risk of developing severe COVID-19. Dr Klipstein further emphasised the important role of fertility specialists in promoting vaccination to their patients, their communities and the public, so as to counter worrying trends of vaccine hesitancy.

During the event, attendees were polled on whether they thought a consensus was needed between all relevant professional bodies on the COVID vaccine and fertility treatment. A clear majority (77 percent) voted yes, prompting Norcross to ask the panel if there was any hope of a consensus being worked out. All three speakers agreed that a uniform message would help avoid confusion and vaccine hesitancy, but that it would be difficult to achieve a consensus, due to each national body's need to follow the formal position of their country's health authorities. The speakers did, however, note that there was significant agreement on key points.

While most of the discussion focused on vaccination of women and the impact on pregnancy, there was an audience question about the impact vaccination might have on sperm quality. The panel agreed that there is no suggestion of risk to the quality of sperm, but that it might be beneficial for men to leave some time between vaccination and fertility treatment, simply to avoid any temporary side effects of the vaccine (such as a fever) having an effect on sperm production. However, it remains prudent for men to get vaccinated before a planned conception, not least so that they avoid the risk of transmitting COVID-19 to the pregnant woman.

Several audience questions addressed the lack of evidence available on the impact of the vaccine. The panel agreed that while there is currently little evidence on the impact of the vaccines on IVF treatment, gamete donation or the health of newborns, there is new information coming in constantly and at unprecedented speeds. Studies of long-term effects will by their nature take time, but there is reassurance to be drawn from studies undertaken on other non-live vaccines.

Dr Klipstein warned against the temptation of an overabundance of caution in the absence of data, as this could end up forcing women into an impossible scenario of weighing up the risk posed by COVID-19 to their own health with any theoretical risks to their baby from the vaccine. Professor Kasraie observed that IVF patients are known to be especially anxious during the pregnancy, so placing them in a position where they have to shield throughout the nine months of pregnancy for fear of catching COVID-19 could exacerbate their isolation and anxiety.

Overall, the event showed that despite some differences in the advice given by UK, EU and US bodies, there is significant agreement on the important role of vaccination in protecting the health of fertility patients and professionals alike. Evidence of the harm that can be caused by COVID-19 during pregnancy is clear, known and real. Evidence of harm that can be caused by COVID vaccines is at best theoretical and unsupported by evidence. Certain precautions may be taken in the absence of data, but it is important to ensure that such precautions are not taken to be an indication that there is a known risk.

PET is grateful to the Edwards and Steptoe Research Trust Fund, the British Fertility Society, the Bristol Fertility Clinic and CooperSurgical for supporting this event.

See the rest here:
The COVID Vaccine: A Shot in the Arm for Fertility Treatment? - BioNews

ACAAI Annual Scientific Meeting 2020

After closely monitoring the ongoing COVID-19 pandemic and its continuing impact on our patients, practices and country, the American College of Allergy, Asthma & Immunology has made the decision to deliver the ACAAI 2020 Annual Scientific Meeting as a 3-day, fully-virtual event, instead of meeting face-to-face in Phoenix this November.

The health and well-being of our conference attendees and faculty members is our top priority, and moving to a virtual platform ensures that we can offer an uncompromised program that is safe and filled with the outstanding content you have come to expect from the College.

See the article here:
ACAAI Annual Scientific Meeting 2020

Home | CIML

Eric VIVIER and Bernard MALISSEN, team leaders at the Marseille-Luminy Immunology Center, are on the 2020 list of the most cited researchers in the world for the fourth time, as in previous editions 2016, 2017, 2018 and 2019.Published annually by the prestigious Clarivate Analytics Company, previously Thomson Reuters, this ranking recognizes authors of the most frequently cited publications in the scientific community.A recognition mark that rewards the value of their discoveries and the exceptional research influence in their scientific field.

See the list

Initial translational analysis, EXPLORE, showed overexpression of C5a/C5aR pathway in patients with severe COVID-19The primary objective of this investigator-sponsored trial, named FORCE, is to improve the proportion of COVID-19 patients with severe pneumonia who no longer need to be hospitalized, and to reduce the need for and duration of mechanical ventilation in patients with COVID-19 pneumonia complicated by acute respiratory distress syndrome (ARDS).

Through the translational data analysis in COVID-19 patients, we observed high levels of circulating C5a and over-activation of the C5a-dependent myeloid cell pathway, which is believed to contribute to inflammation in the lungs. Avdoralimab is a monoclonal antibody that blocks C5aR and has the potential to reduce the inflammatory response in the lungs, said Pr. Eric Vivier, PhD, Chief Scientific Officer at Innate Pharma and Professor at AP-HM (Marseille Public University Hospitals), Aix-Marseille University and Centre dImmunologie de Marseille-Luminy, CNRS, Inserm and AMU.More information

A Franco-German research team led by Prof. Michael Sieweke, from the Center for Regenerative Therapies TU Dresden (CRTD) and the Center of Immunology of Marseille Luminy (CNRS, INSERM, Aix-Marseille University), today uncovered a surprising property of blood stem cells: not only do they ensure the continuous renewal of blood cells and contribute to the immune response triggered by an infection, but they can also remember previous infectious encounters to drive a more rapid and more efficient immune response in the future. These findings should have a significant impact on future vaccination strategies and pave the way for new treatments of an underperforming or over-reacting immune system. The results of this research are published in Cell Stem Cell on March 12, 2020. More information

C/EBP-Dependent Epigenetic Memory Induces Trained Immunity in Hematopoietic Stem Cellsde Laval B., Maurizio J., Kandalla P K., Brisou G., Simonnet L., Huber C., Gimenez G., Matcovitch-Natan O., Reinhardt S., David E., Mildner A., Leutz A., Nadel B., Bordi C., Amit I., Sarrazin S.*,., Sieweke M H.*,. Cell Stem Cell, 2020 , pii: S1934-5909(20)30017-5, PMID: 32169166

See the original post:
Home | CIML